Botox Rival Can Stay On Market Following Allergan Deal
Evolus and Allergan announced a deal Friday that resolves trade secret theft allegations against Evolus, allowing Evolus' low-cost version of Allergan's Botox to stay on the market in the U.S. in...To view the full article, register now.
Already a subscriber? Click here to view full article